Drug Pricing: US House, Senate, Taking Bicameral Go-Slow Approach
Energy & Commerce Health Subcommittee hearing on drug pricing and the supply chain begins information gathering process, leadership says. Subcommittee Chair Burgess urges stakeholders to seek consensus on market-based solutions – or else.
You may also be interested in...
Letter to seven pharmacy benefit managers seeks insight into pros and cons of practices, suggesting that policymakers understand PBMs bring value in lowering costs but that some activities are counterproductive.
Sen. Sanders and Rep. Cummings requested the study, which notes industry's healthy margins and offers concerns about mergers – but emphasizes the increasing cost of R&D.
Measures that would increase financial transparency and empower federal government to negotiate drug prices highlighted by National Academies representative who discussed recent report on drug affordability, but former Congressional Budget Office Director Holtz-Eakin warns Senate HELP Committee against taking measures that merely shift costs from one party to another.